AVLN Financials

Income Statement
MetricQ2 2026
Revenue
0
Cost of Revenue
0
Gross Profit
0
Operating Expenses
31.3M
R&D
24.7M
SG&A
6.6M
Operating Income
-31290000
EBITDA
-31180000
Net Income
-28935000
EPS (Basic)
$-0.98
EPS (Diluted)
$-0.98
Shares (Diluted)
29.7M
MarketsMoversWatchlist
Avalyn Pharma (AVLN) — Financials